<DOC>
	<DOC>NCT02326220</DOC>
	<brief_summary>This is a randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effect of alirocumab in comparison with placebo on the frequency of LDL apheresis treatments in patients with HeFH undergoing LDL apheresis therapy.</brief_summary>
	<brief_title>Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>1. Men and women â‰¥18 years of age at the time of the screening visit 2. Diagnosis of HeFH (Heterozygous familial hypercholesterolemia) 3. Currently undergoing LDL (lowdensity lipoprotein) apheresis therapy QW (weekly) or Q2W (every 2 weeks) or at least 8 weeks prior to the screening visit 1. Homozygous FH (familial hypercholesterolemia) 2. Background medical LMT (lipidmodifying therapy) (if applicable) that has not been stable for at least 8 weeks prior to the screening visit 3. LDL apheresis schedule/ apheresis settings that have not been stable for at least 8 weeks prior to the screening visit 4. An LDL apheresis schedule other than QW to Q2W 5. Initiation of a new exercise program or exercise that has not remained stable within 8 weeks prior to the screening visit (week 2) 6. Initiation of a new diet or a diet that has not been stable within 8 weeks prior to the screening visit (week 2) 7. Use of nutraceuticals or overthecounter therapies known to affect lipids, at a dose/amount that has not been stable for at least 8 weeks prior to the screening visit (week 2), or between the screening and randomization visit 8. Presence of any clinically significant uncontrolled endocrine disease known to influence serum lipids or lipoproteins 9. Known history of a positive test for human immunodeficiency virus 10. Use of any active investigational drugs within 1 month or 5 halflives of screening, whichever is longer 11. Patients who have been treated with at least 1 dose of alirocumab or any other antiPCSK9 monoclonal antibody in any other clinical studies 12. Pregnant or breastfeeding women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>